Compare Ascendis Pharma A/S (ASND) vs HP Inc (HPQ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs HP Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while HP Inc trades at $24.17 (market cap $22.15B). The key difference: HP Inc is the larger of the two by market cap, and HP Inc pays a 4.95% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | HPQ | |
|---|---|---|
Market Cap | $17.74B | $22.15B |
Sector | Health | Technology |
52-Week High | $277.18 | $29.35 |
52-Week Low | $163.32 | $18.20 |
Enterprise Value | $18.11B | $29.31B |
Dividend Yield | — | 4.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
HPQ trades at $24.22, up 0.37% today, with a bullish technical outlook and strong recent earnings beats. The stock shows attractive valuation with a P/E of 8.97 and P/S of 0.4, supported by consistent operating cash flow of $3.7B in 2025. Recent news highlights HP's AI PC partnerships and dividend yield near 5%, though revenue growth remains modest amid industry headwinds.
Outlook is cautiously positive given low valuation and dividend appeal, but risks include PC market volatility and competitive pressures. Analyst consensus is mixed with a $22 price target below current levels, suggesting limited near-term upside despite fundamental strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About HP Inc
HP Incorporated is a leading provider of computers, printers, and printer supplies. The company's mains segments are personal systems and printing. Its personal systems segment contains notebooks, desktops, and workstations. Its printing segment contains supplies, consumer hardware, and commercial hardware. In 2015, Hewlett-Packard was separated into HP Incorporated and Hewlett Packard Enterprise and the Palo Alto, California-based HP Incorporated sells on a global scale.
Read more on HPQ →
